ストックスクリーナーアプリを入手
5.30
1.12%
-0.06
アフターアワーズ：
5.35
0.05
+0.94%
前日終値:
$5.36
開ける：
$5.28
24時間の取引高:
12,187
Relative Volume:
0.20
時価総額：
$91.05M
収益：
$37.16M
当期純損益:
$-17.83M
株価収益率:
-5.1257
EPS:
-1.034
ネットキャッシュフロー:
$-14.22M
1週間 パフォーマンス:
-6.85%
1か月 パフォーマンス:
-2.03%
6か月 パフォーマンス:
-0.56%
1年 パフォーマンス:
+2.71%
1日の値動き範囲:
$5.25
$5.525
1週間の範囲:
$5.22
$5.8308
52週間の値動き範囲:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
名前
Verrica Pharmaceuticals Inc
セクター
電話
484-453-3300
住所
44 WEST GAY STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.30 | 83.49M | 37.16M | -17.83M | -14.22M | -1.034 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-06 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | アップグレード | Needham | Hold → Buy |
| 2023-03-22 | 開始されました | Jefferies | Buy |
| 2023-02-13 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-12-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-06-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-24 | 開始されました | Northland Capital | Outperform |
| 2020-03-24 | 開始されました | Needham | Buy |
| 2019-02-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Verrica Pharmaceuticals Inc (VRCA) 最新ニュース
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills - MyChesCo
Verrica Pharmaceuticals Inc. (VRCA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Verrica completes enrolment in Phase III trial of Ycanth - clinicaltrialsarena.com
Verrica Completes Enrollment in Phase 3 YCANTH Common Warts Trial - Dermatology Times
VRCA Looks 46.0% Undervalued on GF Value™ Despite Speculative Ri - GuruFocus
Verrica Pharmaceuticals Announces Completion of Enrollment - globenewswire.com
Verrica (VRCA) Financial Results: EPS Comes in Below Forecast in the Reported Period; Price Move: Shares Fall 0.82% for the Current SessionGuidance Revision Trend - vinanet.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Verrica (VRCA) Financial Results: EPS Misses Its Estimate in Latest Trading; Trading-Day Reaction: Shares Move 4.29% Lower on the DayReturn On Capital - vinanet.vn
VRCA Looks 50.3% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock - MarketBeat
Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares - MarketBeat
Verrica (NASDAQ: VRCA) interim CFO adds 5,000 shares in open-market buy - Stock Titan
Verrica (NASDAQ: VRCA) CEO buys 25,000 shares in August - Stock Titan
Verrica (VRCA) Q2 2026 Earnings Call Transcript - AOL.com
Verrica Pharmaceuticals Inc (VRCA) (Q2 2026) Earnings Call Highl - GuruFocus
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Verrica Revenue Falls Despite Record YCANTH Demand - MyChesCo
Verrica Pharmaceuticals (VRCA) Holds Steady at $5.08 as Range Trade PersistsTick Index - dars.gov.et
Verrica Pharmaceuticals Inc. R (1NE0.DU) balance sheet - Yahoo Finance UK
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc. R (1NE0.DU) stock price, news, quote and history - Yahoo Finance UK
Verrica Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Verrica secures $27.5 million credit facility from chairman By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results - MarketBeat
Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise - Investing.com
Verrica Pharmaceuticals earnings missed by $0.08, revenue topped estimates - Investing.com Canada
Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison - TradingKey
Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings - GuruFocus
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verrica Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verrica Pharmaceuticals Inc. 2026: Revenue $5.86M, EPS ($0.62) — 10-Q Summary - TradingView
Verrica secures $27.5 million credit facility from chairman - Investing.com
Verrica Reports Q2 Revenue of $5.9 Million as YCANTH Demand Rises - Quiver Quantitative
Verrica Pharmaceuticals reports Q2 2026 revenue $5.9M, net loss $13.2M; YCANTH demand up - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Q2 FY2026 earnings call transcript - Yahoo Finance
Verrica Pharma reports wider-than-expected Q2 adj loss per share - TradingView
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results - The Manila Times
YCANTH applicator units reach 19,626; common-wart data expected mid-2027 - Stock Titan
Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - Moomoo
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - GlobeNewswire
Verrica Schedules Aug. 6 Earnings Call With Corporate Update - MyChesCo
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Verrica Pharmaceuticals Inc. R (1NE0.DU) Options Chain - Yahoo! Finance Canada
Graphique interactif des capital-actions 1NE0.SG| Capital-actions Verrica Pharmaceuticals Inc. - Yahoo Finance France
Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday - MarketBeat
Verrica Pharmaceuticals to Report Second Quarter 2026 - GlobeNewswire
Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 - Yahoo Finance
Verrica Pharmaceuticals (VRCA) Slips Over 4% as Shares Test Near-Term Support at $4.92Dark Pool Prints - dars.gov.et
Verrica Expands YCANTH Rights to Israel in Licensing Deal - MyChesCo
Verrica Pharmaceuticals Inc (VRCA) 財務データ
収益
当期純利益
現金流量
EPS
Verrica Pharmaceuticals Inc (VRCA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Rieger Jayson | CEO and President |
Aug 14 '26 |
Buy |
5.06 |
20,000 |
101,200 |
202,593 |
| Rieger Jayson | CEO and President |
Aug 17 '26 |
Buy |
4.91 |
5,000 |
24,550 |
207,593 |
| Rosenberg Noah L. | CMO |
Aug 17 '26 |
Buy |
4.91 |
4,200 |
20,622 |
6,557 |
| Rosenberg Noah L. | CMO |
Aug 18 '26 |
Buy |
4.92 |
2,030 |
9,988 |
8,587 |
| Kirby John J. | Interim CFO |
Aug 18 '26 |
Buy |
4.93 |
5,000 |
24,650 |
23,962 |
| Rosenberg Noah L. | CMO |
Nov 25 '25 |
Buy |
4.24 |
2,357 |
10,000 |
2,357 |
| Kirby John J. | Interim CFO |
Nov 25 '25 |
Buy |
4.24 |
3,536 |
15,001 |
8,962 |
| Zawitz David | Chief Operating Officer |
Nov 25 '25 |
Buy |
4.24 |
10,000 |
42,425 |
21,000 |
| Rieger Jayson | CEO and President |
Nov 25 '25 |
Buy |
4.24 |
94,311 |
400,114 |
182,593 |
| Manning Paul B | Director |
Nov 25 '25 |
Buy |
4.24 |
2,750,762 |
11,670,108 |
3,348,372 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):